Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peripheral neuropathy in multiple sclerosis patients treated with teriflunomide
2021-002810-15Phase 4Completed
- Sponsor
- CHU Brugmann
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of teriflunomide in multiple sclerosis (MS), sponsored by CHU Brugmann. Primary endpoint: Incidence of peripheral nerve abnormalities on nerve conduction studies. Started Jun 2021; status: completed.
02
Drugs
teriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2021-002810-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002810-15.